An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2016
Price : $35 *
At a glance
- Drugs Gevokizumab (Primary)
- Indications Schnitzler syndrome
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors ADIR; IRIS; Servier
- 02 Mar 2016 Status changed from recruiting to completed, according to European Clinical Trials Database record.
- 12 Nov 2013 New trial record